|本期目录/Table of Contents|

[1]沈凯凯综述,吕镗烽审校.外泌体在非小细胞肺癌中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2018,20(04):399-403.[doi:10.3969/j.issn.1672-271X.2018.04.016]
点击复制

外泌体在非小细胞肺癌中的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第20卷
期数:
2018年04期
页码:
399-403
栏目:
综述
出版日期:
2018-07-20

文章信息/Info

Title:
-
作者:
沈凯凯综述; 吕镗烽审校
作者单位：241000 芜湖，皖南医学院(沈凯凯)；210002 南京，南京军区南京总医院呼吸内科（吕镗烽）
Author(s):
-
关键词:
外泌体; 非小细胞肺癌; 诊断; 预后
Keywords:
-
分类号:
R734
DOI:
10.3969/j.issn.1672-271X.2018.04.016
文献标志码:
A
摘要:
肺癌作为全球发病率及死亡率最高的恶性肿瘤，已经严重威胁着人类的健康。外泌体起源于多泡体的纳米级脂质膜囊泡，由于其在血液中存在的稳定性以及与肿瘤细胞密切的同源性，目前作为一个最有前途的研究方向，已经被发现广泛存在于各种健康人群和恶性肿瘤患者的体液中。同时有研究强调了外泌体miRNAs在不同类型的肿瘤中的作用，其中包括肺癌，提示其作为生物标志物和潜在的治疗药物的应用，为肺癌患者的治疗带来新的曙光。文章就外泌体生物学功能和临床应用前景以及外泌体miRNAs作为肺癌诊断和预后进行综述。
Abstract:
-

参考文献/References:

[1]Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. Ca-Cancer J Clin, 2017, 67(1):7.
[2]Méry B, Guy JB, Swalduz A, et al. The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience[J]. Crit Rev Oncol Hema, 2015, 96(2):319.
[3]Hirsch FR, Suda K, Wiens J, et al. New and emerging targeted treatments in advanced non-small-cell lung cancer[J]. Lancet, 2016, 388(10048):1012.
[4]Heerink WJ, de Bock GH, de Jonge GJ, et al. Complication rates of CT-guided transthoracic lung biopsy:meta-analysis[J].Eur Radiol,2016, 27(1):138-148.
[5]Pérezcallejo D, Romero A, Provencio M, et al. Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring[J].Transl lung Cancer Res, 2016, 5(5):455.
[6]张扬, 范小乐, 陈和平,等. 外泌体在胃癌中的研究进展[J]. 医学研究生学报, 2017,30(10):1096-1099.
[7]Yáez-Mó M, Siljander RM, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions[J].J Extracell Vesicles, 2015, 4:27066.
[8]Marcus ME, Leonard JN. FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver[J]. Pharmaceuticals, 2013, 6(5):659-680
[9]Van d PE, Bing AN, Harrison P, et al. Classification, functions, and clinical relevance of extracellular vesicles[J]. Pharmacolrev Rev, 2012, 64(3):676.
[10]Johnstone RM, Adam M, Hammond JR, et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes)[J]. J Biol Chem, 1987, 262(19):9412-9420
[11]Condevancells J, Rodriguezsuarez E, Embade N, et al. Characterization and Comprehensive Proteome Profiling of Exosomes Secreted by Hepatocytes[J].J Proteome Res, 2008, 7(12):5157-5166.
[12]Mathivanan S, Simpson RJ. ExoCarta: A compendium of exosomal proteins and RNA[J]. Proteomics,2009,9(21):4997-5000
[13]Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection[J]. Cell Res, 2014, 24(6):766.
[14]Valadi H, Ekstrm K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells[J]. Nat Cell Biol,2007,9(6):654-659.
[15]李玉静, 刁振宇, 薛平平,等. 血清中胎盘来源外泌体的分离与鉴定[J]. 医学研究生学报, 2015,28(6):632-636.
[16]Shao Y, Shen Y, Chen T, et al. The functions and clinical applications of tumor-derived exosomes[J]. Oncotarget, 2016, 7(37):60736-60751.
[17]Hegmans JP, Bard MP, Hemmes A, et al. Proteomic analysis of exosomes secreted by human mesothelioma cells[J]. M J Pathol, 2004, 164(5):1807-1815.
[18]Krug AK, Karlovich C, Koestler T, et al. Abstract B136:Plasma EGFR mutation detection using a combined exosomal RNA and circulating tumor DNA approach in patients with acquired resistance to first-generation EGFR-TKIs[J]. Am Assoc Cancer Res. 2016，14:B136.
[19]Brinkmann K, Enderle D, Koestler T, et al. Abstract 545: Plasma-based diagnostics for detection of EML4-ALK fusion transcripts in NSCLC patients[J]. Cancer Res, 2015, 75(15 Supplement):545-545.
[20]Al-Nedawi K, Meehan B, Kerbel RS, et al. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR[J]. P Natl Acad Sci USA, 2009, 106(10):3794-3799.
[21]Rahman MA, Barger JF, Lovat F, et al. Lung cancer exosomes as drivers of epithelial mesenchymal transition[J]. Oncotarget, 2016, 7(34):54852.
[22]Usó M, Jantus-Lewintre E, Sirera R, et al. miRNA detection methods and clinical implications in lung cancer[J]. Future Oncol, 2014, 10(14):2279-2292.
[23]Giallombardo M, Chacártegui BJ, Castiglia M, et al. Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients’ Plasma Through qPCR: A Feasible Liquid Biopsy Tool[J]. J Vis Exp, 2016(111). doi: 103791/53900
[24]Wang Y, Yi J, Chen X, et al. The regulation of cancer cell migration by lung cancer cell-derived exosomes through TGF-β and IL-10[J]. Oncol Lett, 2016, 11(2):1527.
[25]Rabinowits G, Gerel-Taylor C, Day JM, et al. Exosomal microRNA: a diagnostic marker for lung cancer[J]. Clin Lung Cancer, 2009, 10(1):42-46.
[26]Cazzoli R, Buttitta F, Nicola MD, et al. MicroRNAs derived from circulating exosomes as non-invasive biomarkers for screening and diagnose lung cancer[J]. J Thorac Oncol, 2013, 8(9):1156.
[27]Leidinger P, Backes C, Dahmke IN, et al. What makes a blood cell based miRNA expression pattern disease specific? - A miRNome analysis of blood cell subsets in lung cancer patients and healthy controls[J].Oncotarget, 2014, 5(19):9484-9497.
[28]Carina R, Isabel S, Klaus P, et al. Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors[J]. PLoS One, 2012, 7(6):e38248.
[29]Rodríguez M, Silva J, Lópezalfonso A, et al. Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer[J].Gene Chromosome Canc, 2014, 53(9):713-724.
[30]Silva J, García V, Zaballos , et al. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival.[J]. Eur Respir J, 2011, 37(3):617.
[31]Rolfo C, Chacartegui J, Giallombardo M, et al. 71P Exosomes isolated in plasma of non-small cell lung cancer patients contain microRNA related to the EGFR pathway: Proof of concept[J].J Thorac Oncol, 2016, 11(4):S85-S85.
[32]Giallombardo M, Jorge Chacartegui J, Reclusa P, et al. Follow up analysis by exosomal miRNAs in EGFR mutated non-small cell lung cancer (NSCLC) patients during osimertinib (AZD9291) treatment: A potential prognostic biomarker tool[J]. J Clin Oncol, 2016,34:abstre23035.
[33]Harel SA, Benmoshe NB, Aylon Y, et al. Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth[J]. Cell Death Differ, 2015, 22(8):1328-1340
[34]Hsu YL, Hung JY, Chang WA, et al. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1[J]. Oncogene, 2017, 36（34）: 4929-4942.
[35]Cui H, Seubert B, Stahl E, et al. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes[J]. Oncogene, 2015, 34(28):3640-3650
[36]Tominaga N, Kosaka N, Ono M, et al. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier[J]. Nat Commun, 2015, 6:6716.
[37]Zhou W, Fong MY, Min Y, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis[J]. Cancer Cell, 2014, 25(4):501-515.
[38]Dinh TT, Wojciech F, Justyna CF, et al. Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer[J]. Radiat Oncol, 2016, 11(1):61.
[39]Yuan D, Xu J, Wang J, et al. Extracellular miR-1246 promotes lung cancer cell proliferation and enhances radioresistance by directly targeting DR5[J]. Oncotarget, 2016, 7(22):32707-32722.
[40]Tang Y, Cui Y, Li Z, et al. Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells[J].J Eep Clin Cancer Res, 2016, 35:20
[41]Li J, Yu J, Zhang H, et al. Exosomes-Derived MiR-302b Suppresses Lung Cancer Cell Proliferation and Migration via TGFu03b2RII Inhibition[J].Cell Physiol Biochem, 2016, 38(5):1715-1726.
[42]Kotmak M, Bozok V. Extracellular Vesicles as Natural Nanosized Delivery Systems for Small-Molecule Drugs and Genetic Material: Steps towards the Future Nanomedicines[J]. J Pharm Pharm Sci, 2015, 18(3):396.
[43]Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges[J]. Acta Pharm Sin B, 2016, 6(4):287-296.
[44]Johnsen KB, Gudbergsson JM, Skov MN, et al. A comprehensive overview of exosomes as drug delivery vehicles-Endogenous nanocarriers for targeted cancer therapy[J]. Bba-Biomembranes, 2014, 1846(1):75-87.
[45]Théry C, Ostrowski M, Segura E, et al. EMembrane vesicles as conveyors of immune responses[J]. Nat Rev Immunol,2009, 9(8):581-593.
[46]Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes[J].Nat Med,1998, 4(5):594-600
[47]Morse MA, Garst J, Osada T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer[J]. J Transl Med, 2005, 3(1):9.
[48]Besse B, Charrier M, Lapierre V, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC[J]. Oncoimmunology, 2016, 5(4):e1071008.

相似文献/References:

[1]周诚忠,夏炎春,夏海波.三维适形放射治疗老年非小细胞肺癌60例[J].医学研究与战创伤救治(原医学研究生学报),2009,11(01):20.
　ZHOU Cheng-zhong,XIA Yan-chun,XIA Hai-bao.Analysis of curative effect on 60 elderly non-small cell lung cancer patients treated by three-dimensional conformal radiotherapy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(04):20.
[2]洪原城,林平冬,张江灵,等.晚期非小细胞肺癌骨转移的骨相关事件 及生存分析[J].医学研究与战创伤救治(原医学研究生学报),2009,11(02):124.
　HONG Yuan-cheng,LIN Ping-dong,ZHANG Jiang-ling,et al.Skeletal-related events of skeletal metastases in advanced stage non-small cell lung cancer and survival analysis[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(04):124.
[3]陈芳芳 综述,李晓军 审校.细胞凋亡在介导非小细胞肺癌耐药调节中的作用[J].医学研究与战创伤救治(原医学研究生学报),2015,17(03):286.[doi:10.3969/j.issn.1672-271X.2015.03.020]
[4]周向毅,丁妍,陈邦元,等.复方康复灵对体部伽玛刀治疗非小细胞肺癌引起的急性放射反应的防护作用[J].医学研究与战创伤救治(原医学研究生学报),2015,17(05):455.[doi:10.3969/j.issn.1672-271X.2015.05.002]
　ZHOU Xiang-yi,DING Yan,CHEN Bang-yuan,et al.Protective effect of compound Kangfuling on body gamma knife in treating acute radiation reaction of non-small cell lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(04):455.[doi:10.3969/j.issn.1672-271X.2015.05.002]
[5]周小林.CRP和Alb与初诊断的非小细胞肺癌临床病理特征联系及预后价值分析[J].医学研究与战创伤救治(原医学研究生学报),2016,18(05):489.[doi:10.3969/j.issn.1672-271X.2016.05.012]
　ZHOU Xiao-lin.Prognostic evaluation of CRP and Alb in newly diagnosed non-small cell lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(04):489.[doi:10.3969/j.issn.1672-271X.2016.05.012]
[6]徐瑞彤,孙康俊,戴冠群,等.抗雌激素治疗对耐酪氨酸激酶抑制剂非小细胞肺癌细胞株抗增殖作用的机制探讨[J].医学研究与战创伤救治(原医学研究生学报),2017,19(06):581.[doi:10.3969/j.issn.1672-271X.2017.06.006]
　XU Rui-tong,SUN Kang-jun,DAI Guan-qun,et al.The antitumor effect of anti-estrogen therapy on non-small cell lung cancer cell lines with acquired resistance to EGFR-TKI[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2017,19(04):581.[doi:10.3969/j.issn.1672-271X.2017.06.006]
[7]张驰,张久荣,童维佳,等.芪胶升白胶囊对改善非小细胞肺癌患者化疗所致中性粒细胞减少症的临床药物疗效研究与分析[J].医学研究与战创伤救治(原医学研究生学报),2018,20(01):26.[doi:10.3969/j.issn.1672-271X.2018.01.006]
　ZHANG Chi,ZHANG Jiu-rong,TONG Wei-jia,et al.Study and analysis on clinical drug efficacy of Qijiaoshengbai capsule on the treatment of non-small cell lung cancer patients with neutropenia caused by chemotherapy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(04):26.[doi:10.3969/j.issn.1672-271X.2018.01.006]
[8]张艳综述,梁元姣审校.外泌体在胚胎植入中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2019,21(4):397.[doi:10.3969/j.issn.1672-271X.2019.04.014]
　Yan ZHANGreviewing,Yuan-jiao LIANGchecking.Advances in exosomes in embryo implantation[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2019,21(04):397.[doi:10.3969/j.issn.1672-271X.2019.04.014]
[9]朱皓皞综述,梅金红审校.外泌体液体活检及其在肿瘤诊断治疗中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2019,21(5):512.[doi:10.3969/j.issn.1672-271X.2019.05.014]
　ZHU Hao-hao,MEI Jin-hong.Advances in liquid biopsy of exosomes and its application in diagnosis and treatment of tumors[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2019,21(04):512.[doi:10.3969/j.issn.1672-271X.2019.05.014]
[10]王毅,权琳.培美曲塞与顺铂联合吉非替尼治疗对非小细胞肺癌患者T细胞亚群及细胞因子的影响[J].医学研究与战创伤救治(原医学研究生学报),2020,22(01):43.[doi:10.3969/j.issn.1672-271X.2020.01.010]
　WANGYi,QUANLin.Effects of pemetrexed and cisplatin combined with gefitinib on T cell subsets and cytokines in patients with lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(04):43.[doi:10.3969/j.issn.1672-271X.2020.01.010]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2018-07-20